Using this system (in a large series of BCP‐ALL and T‐ALL cell lines), we verified the association of both wild‐type NUDT15 genotype and NT5C2 and PRPS1 mutations with a resistance to 6MP at concentrations pharmacologically relevant to the clinical setting. The gene discussed is PRPS1; the disease is acute lymphoblastic leukemia.